A New Tool Helps People With Type 1 Diabetes Stay in Target Blood Sugar Range

STUDIA is a decision-support system—essentially a digital tool designed to help people with Type 1 diabetes make better insulin dosing decisions at mealtime. Rather than relying on carbohydrate counting alone, STUDIA uses what researchers call a 'digital twin': a personalized computer model that simulates how your individual body might respond to a given dose of insulin.

The system runs simulations before suggesting an insulin dose, aiming to keep your blood sugar in a healthy range while minimizing the risk of low blood sugar. Think of it as having a virtual assistant that knows your glucose patterns and helps predict the best dose for each meal.

Researchers in this randomized trial divided 28 people with Type 1 diabetes into two groups. One group used STUDIA's simulation-assisted bolus calculator; the other continued with traditional carbohydrate counting. All participants wore continuous glucose monitors (Freestyle Libre) to track their blood sugar throughout the study.

After four weeks, the STUDIA group spent significantly more time in their target glucose range (70–180 mg/dL)—a 7% improvement compared to the traditional counting group. They also had markedly fewer hypoglycemic episodes, with a 69% relative reduction in low blood sugar events.

When researchers tested how accurately STUDIA's predictions matched actual glucose readings, the system showed a mean error of about 19% at the 60-minute mark, with errors growing larger further out in time. Importantly, most of these prediction errors fell into no-risk or slight-risk zones, suggesting the system remained safe even when not perfectly precise.

Spending more time in range and experiencing fewer lows are meaningful goals for people with Type 1 diabetes. Better glucose control can help reduce the long-term risk of diabetes complications, and fewer hypoglycemic events mean less anxiety and fewer dangerous episodes.

Decision-support systems like STUDIA may also address a real challenge: many people worldwide manage Type 1 diabetes with multiple daily injections or pump therapy alone, without additional tools to optimize dosing. Researchers note that systems like this could be cost-effective ways to improve both treatment adherence and glucose outcomes.

This study involved only 28 participants over a four-week period. To understand whether STUDIA would work reliably for larger, more diverse populations over longer timeframes, more extensive research is needed.

The study was 'open-label,' meaning participants knew which group they were in, which can sometimes influence results. Larger, longer, and more rigorously controlled trials would provide stronger evidence of the system's real-world benefit.

STUDIA is a research tool at this stage. It is not yet widely available as a clinical product, and this early positive finding does not mean it will work the same way for everyone or replace the need for medical supervision and personalized care.

Origin: nature.com (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.